Novavax Inc - Search News

Novavax cuts 2024 revenue forecast

Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls

On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, beating the consensus of $65.78 million. Product sales of $38 million for the third quarter of 2024 were primarily related to U.

Reuters on MSN · 13h

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi. The U.S. vaccine maker now expects between $175 million and $225 million for full-year sales of its COVID vaccine,

Investopedia on MSN · 10h

Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again

Key Takeaways Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results.The company has cut its guidance multiple times this year, and the new range is below the analyst consensus.

Seeking Alpha on MSN · 12h

Novavax falls after guidance cut on lower vaccine sales

Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 financials, cut its full-year revenue guidance, citing a gloomy sales outlook for its COVID-19 vaccine,

Novavax to Move Forward With Covid-19-Flu Vaccine

Daily · 21h

USFDA removes clinical hold on Novavax COVID Influenza combination, stand alone Influenza Phase 3 trial

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that the U.S. Food and Drug Administration (USFDA) has removed the

Business Insider · 1d

Novavax: FDA removes clinical hold on Covid-19/flu combo trial

Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its

MarketWatch · 1d

Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update

Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold. The Gaithersburg, Md., vaccine developer said Monday that the U.S. Food and Drug Administration had removed the clinical hold on its investigational new drug application for its combined vaccine and its standalone flu vaccine candidates.

Hosted on MSN11h

Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss

Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...

Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

MarketWatch4h

Novavax Inc. stock underperforms Tuesday when compared to competitors

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...

13h

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

13h

Novavax Cuts FY24 Revenue View Below Market; Stock Drops In Pre-market - Update

Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...

14h

Novavax: Q3 Earnings Snapshot

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...

Seeking Alpha9h

Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?

On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...

10h

Novavax, Inc.: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average Target Price from Analysts

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novavax cuts 2024 revenue forecast

Novavax to Move Forward With Covid-19-Flu Vaccine

Related topics